查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447722

轉移性大腸直腸癌市場評估：按治療類型、診斷、最終用戶和地區劃分的機會和預測（2017-2031）

Metastatic Colorectal Cancer Market Assessment, By Treatment Type, By Diagnosis, By End-user By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 235 Pages | 商品交期: 3-5個工作天內

價格

全球轉移性大腸直腸癌市場規模將從2023年的39.1億美元增長到2031年的51.8億美元，2024-2031年預測期間複合年增長率為3.58%。預計將增長到2031年的51.8億美元。美元。

由於蔬菜和水果攝取不足、過量飲酒、久坐的生活方式、吸煙、肥胖和加工肉類的大量消費，結直腸癌患病率不斷上升，為市場提供了利潤豐厚的增長機會。

轉移性結直腸癌市場的發展得益於醫療領域支出的增加、世界各國政府的大力支持、研發活動的增加以及積極努力開發新的診斷技術和加強現有技術。多種因素，包括 意識的提高、人口老化、政府不斷採取措施提供負擔得起的治療和診斷解決方案，以及有利的報銷政策，也為市場提供了有利的成長機會。

此外，包括食品藥物管理局 (FDA) 在內的各個監管機構越來越多地批准各種診斷和治療解決方案，這進一步推動了市場擴張。 例如，2023年，Foundation Medicine的FoundationOne Liquid CDx被FDA批准為恩科拉非尼和西妥昔單抗聯合治療的伴隨診斷。 FDA 批准此聯合療法用於治療先前接受過 BRAF V600E 突變的轉移性大腸直腸癌患者。

開發新診斷解決方案的研究活動支持市場發展

由於轉移性結直腸癌的死亡率很高，早期檢測對於改善患者預後至關重要，並且正在進行各種研究活動來篩選結直腸癌的轉移性生物標誌物。我是。 例如，伊朗哈馬丹醫科大學的研究人員正在使用實驗驗證和機器學習方法來研究與轉移性大腸直腸癌相關的生物標記。 這項研究的結果在機器學習演算法的幫助下，有望為轉移性大腸直腸癌生物標記的鑑定提供新的見解，並為治療該疾病的創新治療策略奠定基礎。

策略聯盟支持市場拓展

策略聯盟使製藥公司能夠測試和開發新藥，滿足所需的功效和安全標準，並加快藥物開發過程。 此類合作加強了藥品分銷流程並支持藥品的共同開發和商業化。

本報告調查了全球轉移性結直腸癌市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。分析、案例研究、競爭格局、以及主要公司的簡介。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球轉移性大腸直腸癌市場展望

  • 市場規模/預測
  • 依治療類型
    • 化療
    • 手術
    • 標靶治療
    • 放射治療
    • 免疫治療
    • 其他
  • 透過診斷
    • 切片
    • 體外診斷測試
    • 圖片
    • 其他
  • 按最終用戶
    • 醫院
    • 癌症研究所
    • 門診治療中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球轉移性大腸直腸癌市場展望：按地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 依治療類型
  • 透過診斷
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • Amgen, Inc.
  • Sanofi S.A.
  • F. Hoffmann-La Roche AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Co
  • Bayer AG
  • Merck & co., Inc.
  • Abbott Laboratories
  • Bruker Corporation
  • Epigenomics AG

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11129

Global metastatic colorectal cancer market is projected to witness a CAGR of 3.58% during the forecast period 2024-2031, growing from USD 3.91 billion in 2023 to USD 5.18 billion in 2031F. The increasing prevalence of colorectal cancer due to low intake of fruits and vegetables, excessive alcohol consumption, sedentary lifestyle, smoking, obesity, and high intake of processed meats is providing lucrative growth opportunities to the market.

Growth of the metastatic colorectal cancer market is driven by various factors including increased spendings towards healthcare sector, rising support from various governments across the globe, growing research and development activities, and rising efforts towards development of novel diagnostic techniques and enhancement of existing techniques. Increasing awareness, ageing population, and rising government initiatives to provide affordable treatment and diagnostic solutions in combination with the presence of favorable reimbursement policies providing lucrative growth opportunities to the market.

Increasing approval for various diagnostic and treatment solutions by different regulatory bodies including the Food and Drug Administration (FDA) is further supporting the market expansion. For instance, in 2023, the FDA approved Foundation Medicine's FoundationOne Liquid CDx as a companion diagnostic for encorafenib combined with cetuximab. The combination therapy received FDA approval for patients with previously treated metastatic colorectal cancer with BRAF V600E alteration.

FoundationOne Liquid CDx became the first comprehensive genomic profiling test that was approved by the Food and Drug Administration for detecting BRAF V600E mutations in patients with metastatic colorectal cancer. The companion diagnostic indication provides oncologists with non-invasive and important genomic testing solutions for patients with metastatic cancers.

Research Activities for Development of Novel Diagnostic Solutions Support Market Growth

Due to the high fatality rate of metastatic colorectal cancer, early detection is essential for enhancing patient outcomes therefore, various research activities are underway for screening metastatic biomarkers in colorectal cancer. For instance, research is being conducted by the researchers of Hamadan University of Medical Sciences, Hamadan, Iran for the investigation of metastatic colorectal cancer related biomarkers by employing experimental validation and a machine learning approach. The findings of the research are expected to offer novel insights for the identification of biomarkers for metastatic colorectal cancer with the help of machine learning algorithms, laying the groundwork for innovative therapeutic strategies for disease treatment. Through machine learning algorithms 11 biomarkers were identified and 4 were experimentally validated. The joint applications of these genes can augment the development of innovative AI predictive models and can be considered as a diagnostic panel for metastatic assessment.

Strategic Collaborations Support Market Expansion

Strategic collaborations allow pharmaceutical companies to test and develop novel drugs, ensuring that they meet the required efficacy and safety standards, and fast-track the drug development process. Such collaborations bolster the drug distribution process and support the co-development and commercialization of drugs. For instance, Taiho Pharmaceutical, the company that manufactures Lonsurf (trifluridine and tipiracil) signed an exclusive license agreement for commercializing and co-developing the drug with Servier in Europe. In August 2023, Lonsurf received approval from the Food and Drug Administration for treating patients with metastatic colorectal cancer in combination with bevacizumab or as a single agent in patients who were previously treated with anti-epidermal Growth Factor Receptor (EGFR) antibodies, fluoropyrimidine, bevacizumab, oxaliplatin, and irinotecan have been diagnosed with RAS wild-type metastatic colorectal cancer.

North America Accounts for Significant Market Share

It is estimated that colorectal cancer is the fourth most diagnosed cancer among individuals aging 30 to 39 years in the United States. The increasing prevalence of colorectal cancer, presence of a well-established healthcare infrastructure, and increasing investments by leading research institutions and market players towards metastatic colorectal cancer are supporting the market expansion in North America. The high awareness among the regional population about diagnostic devices and testing coupled with government policies is further supporting the market expansion in the region. The rising investments of various market players and research institutions towards research and development activities are providing lucrative growth opportunities to the market.

For instance, the University of Florida is conducting a randomized interventional phase 2 study to investigate the utilization of the standard scan-based approach versus the Signatera ctDNA assay for guiding treatment in patients suffering from metastatic colorectal cancer. The main aim of the study is to compare and measure the best overall response, survival, and progression-free survival of the subjects whose treatment had been developed using these two approaches.

Chemotherapy Holds a Significant Market Share

Utilization of chemotherapy for the treatment of metastatic colorectal cancer relieves symptoms and prolongs the lifespan of the patients. Chemotherapy is used for destroying cancer cells and preventing them from multiplying, dividing, and growing. It is a form of systemic medication that travels through the bloodstream, reaching all the body parts. Doublet chemotherapy or triplet therapy should be offered to patients suffering from initially unresectable and previously untreated metastatic colorectal cancer. Chemotherapy in combination with other therapies and surgeries is recommended for treatment of metastatic colorectal cancer.

For instance, anti-epidermal growth factor receptor therapy and chemotherapy is recommended for proficient mismatch repair left-sided treatment-naive RAS wild-type metastatic colorectal cancer and for proficient mismatch repair RAS wild-type right-sided metastatic colorectal cancer. System chemotherapy plus cytoreductive surgery is often recommended for selected patients, with colorectal peritoneal metastases. Surgery alone or perioperative chemotherapy are offered to patients with metastatic colorectal cancer who are candidates for curative resection of liver metastases.

Advancements in In-vitro Diagnostic Solutions

The continuous advancements in the development of diagnostic solutions are offering lucrative growth opportunities to the market. The advancements are ensuring the provision of quality care to patients suffering from metastatic colorectal cancer and garnering approval from different regulatory bodies. For instance, in 2023, the Food and Drug Administration approved a RAS Mutation Detection Kit as a companion diagnostic for panitum. The kit is expected to increase access to RAS testing at the mid and small-sized laboratories by improving the turnaround time and simplifying the testing procedure while lowering the diagnostic costs. The molecular in-vitro diagnostic tool has been designed for detecting thirty-five variants of KRAS and NRAS exon 2, 3, and 4 somatic mutations in patients suffering from colorectal cancer via the extracted genomic DNA from paraffin-embedded, formalin-fixed embedded colorectal cancer tissue samples.

Future Market Scenario (2024 - 2031F)

Drug delivery systems using bacteria, cell manipulation techniques for immunotherapy, and nanotechnology promise viable and emerging therapeutic options for patients who are not benefitting from the treatment options that are currently available. Combining nanotechnology with immunotherapy and other targeted therapies as a means of delivering drugs that have systemic toxicity and are otherwise non-selective is expected to offer novel strategic venue for the treatment of metastatic colorectal cancer. Emerging technologies in pre-clinical phase studies including immunostimulatory cytokines, microbial therapies, and nanotechnology offer possibilities for therapeutic deliveries.

Key Players Landscape and Outlook

Key participants in the metastatic colorectal cancer market are Amgen, Inc., Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Company, and Bristol-Myers Squibb Co. The market is expected to witness significant growth over the forecast period due to rising research and development activities by the leading market players.

In 2023, Amgen released data from their global Phase 3 CodeBreaK 300 trial that evaluated panitumumab in combination with two doses of sotorasib. The doses showed statistically significant superiority and the results were showcased during the European Society for Medical Oncology (ESMO) 2023. The data showed consistent efficacy across major subgroups and supports the combination of the two biomarker-directed therapies.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Metastatic Colorectal Cancer Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Treatment type
    • 4.2.1.Chemotherapy
    • 4.2.2.Surgery
    • 4.2.3.Targeted Therapy
    • 4.2.4.Radiation Therapy
    • 4.2.5.Immunotherapy
    • 4.2.6.Others
  • 4.3.By Diagnosis
    • 4.3.1.Biopsy
    • 4.3.2.In-vitro Diagnostic Testing
    • 4.3.3.Imaging
    • 4.3.4.Others
  • 4.4.By End-user
    • 4.4.1.Hospitals
    • 4.4.2.Cancer Research Institutes
    • 4.4.3.Ambulatory Care Centers
    • 4.4.4.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.South America
    • 4.5.3.Europe
    • 4.5.4.Asia-Pacific
    • 4.5.5.Middle East & Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Metastatic Colorectal Cancer Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Treatment Type
      • 5.1.2.1.Chemotherapy
      • 5.1.2.2.Surgery
      • 5.1.2.3.Targeted Therapy
      • 5.1.2.4.Radiation Therapy
      • 5.1.2.5.Immunotherapy
      • 5.1.2.6.Others
    • 5.1.3.By Diagnosis
      • 5.1.3.1.Biopsy
      • 5.1.3.2.In-vitro Diagnostic Testing
      • 5.1.3.3.Imaging
      • 5.1.3.4.Others
    • 5.1.4.By End-user
      • 5.1.4.1.Hospitals
      • 5.1.4.2.Cancer Research Institutes
      • 5.1.4.3.Ambulatory Care Centers
      • 5.1.4.4.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Treatment Type
      • 5.1.5.2.1.Chemotherapy
      • 5.1.5.2.2.Surgery
      • 5.1.5.2.3.Targeted Therapy
      • 5.1.5.2.4.Radiation Therapy
      • 5.1.5.2.5.Immunotherapy
      • 5.1.5.2.6.Others
      • 5.1.5.3.By Diagnosis
      • 5.1.5.3.1.Biopsy
      • 5.1.5.3.2.In-vitro Diagnostic Testing
      • 5.1.5.3.3.Imaging
      • 5.1.5.3.4.Others
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospitals
      • 5.1.5.4.2.Cancer Research Institutes
      • 5.1.5.4.3.Ambulatory Care Centers
      • 5.1.5.4.4.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Treatment Type
  • 6.2.By Diagnosis
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Supply Demand Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Patent Landscape
  • 9.2.Regulatory Approvals
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Amgen, Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Sanofi S.A.
  • 13.3.F. Hoffmann-La Roche AG
  • 13.4.Eli Lilly and Company
  • 13.5.Bristol-Myers Squibb Co
  • 13.6.Bayer AG
  • 13.7.Merck & co., Inc.
  • 13.8.Abbott Laboratories
  • 13.9.Bruker Corporation
  • 13.10.Epigenomics AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 4.Global Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 5.Global Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Metastatic Colorectal Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 10.North America Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 11.North America Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 16.United States Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 17.United States Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 21.Canada Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 22.Canada Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 26.Mexico Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 27.Mexico Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 31.Europe Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 32.Europe Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 37.Germany Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 38.Germany Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 42.France Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 43.France Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 47.Italy Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 48.Italy Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 52.United Kingdom Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 53.United Kingdom Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 57.Russia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 58.Russia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 62.Netherlands Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 63.Netherlands Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 67.Spain Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 68.Spain Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 72.Turkey Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 73.Turkey Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 77.Poland Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 78.Poland Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 82.South America Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 83.South America Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 88.Brazil Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 89.Brazil Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 93.Argentina Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 94.Argentina Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 98.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 99.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101.India Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 104.India Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 105.India Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 109.China Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 110.China Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 114.Japan Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 115.Japan Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 119.Australia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 120.Australia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 124.Vietnam Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 125.Vietnam Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 129.South Korea Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 130.South Korea Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 134.Indonesia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 135.Indonesia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 139.Philippines Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 140.Philippines Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 144.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 145.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 150.Saudi Arabia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 151.Saudi Arabia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 155.UAE Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 156.UAE Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 160.South Africa Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 161.South Africa Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023